Orphan medicine, Ramucirumab (Cyramza®), provides long-awaited advance for difficult to treat stomach cancer

First approved therapy specifically indicated for second-line advanced stomach and gastro-oesophageal junction cancer receives marketing authorisation in Europe
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Oncology Latest News Source Type: news